Cero Therapeutics Holdings, Inc.
CERO- Exchange
- OTC
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001870404
No open-market purchases or sales by Cero Therapeutics Holdings, Inc. insiders were filed in the last 90 days; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.
Other share classesCEROW
13F holders, Q4 2024
Institutional positions in Cero Therapeutics Holdings, Inc. as of Dec 31, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 21
- +3 vs. Q3 2024
- Shares held
- 13.3M
- +9.90M (+287.7%) vs. Q3 2024
- Total value
- $800.3K
- +$480.2K (+150.1%) vs. Q3 2024
- New holders
- 11
- 6 more added
- Sold out
- 8
- 0 more reduced
Compare with Q3 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting CERO on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 0 | $0 |
| Q3 2025 | 11 | $798.7K |
| Q2 2025 | 8 | $2.38M |
| Q1 2025 | 15 | $527.7K |
| Q4 2024 | 21 | $800.3K |
| Q3 2024 | 18 | $320.0K |
| Q2 2024 | 15 | $557.1K |
| Q1 2024 | 9 | $4.85M |
| Q4 2023 | 10 | $7.49M |
| Q3 2023 | 10 | $7.33M |
| Q2 2023 | 13 | $10.6M |
| Q1 2023 | 17 | $12.5M |
| Q4 2022 | 46 | $101.1M |
| Q3 2022 | 66 | $153.0M |
| Q2 2022 | 54 | $144.5M |
| Q1 2022 | 45 | $137.2M |
| Q4 2021 | 36 | $104.2M |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q4 2024
Shares, value and share of portfolio for each institution holding Cero Therapeutics Holdings, Inc.; share changes are against Q3 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| ARCH Venture Management, LLC | 9,393,561 | $563.6K | 0.24% | +7,949,265+550.4% | Added |
| Avantax Planning Partners, Inc. | 2,585,151 | $155.1K | 0.01% | +1,224,021+89.9% | Added |
| Cubist Systematic Strategies, LLC | 333,442 | $20.0K | 0.00% | +333,442 | New |
| JustInvest LLC | 234,657 | $14.1K | 0.00% | +234,657 | New |
| Cantor Fitzgerald, L. P. | 155,000 | $10.0K | 0.00% | +155,000 | New |
| Goldman Sachs Group Inc | 162,474 | $9.75K | 0.00% | +162,474 | New |
| Selkirk Management LLC | 121,040 | $7.26K | 0.00% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 73,670 | $4.42K | 0.00% | +68,705+1,383.8% | Added |
| Millennium Management LLC | 63,054 | $3.78K | 0.00% | +63,054 | New |
| Jane Street Group, LLC | 57,459 | $3.45K | 0.00% | +461+0.8% | Added |
| SG Americas Securities, LLC | 25,752 | $2.00K | 0.00% | +25,752 | New |
| Revolve Wealth Partners, LLC | 32,799 | $1.97K | 0.00% | +32,799 | New |
| HBK Sorce Advisory LLC | 26,249 | $1.57K | 0.00% | +26,249 | New |
| Guidance Point Advisors, LLC | 18,717 | $1.12K | 0.00% | +18,717 | New |
| Marex Group plc | 15,000 | $900 | 0.00% | +15,000 | New |
| Birchview Capital, LP | 12,972 | $778 | 0.00% | 00.0% | Unchanged |
| SBI Securities Co., Ltd. | 5,523 | $331 | 0.00% | +5,523 | New |
| Bank of America Corp | 685 | $41 | 0.00% | +453+195.3% | Added |
| Advisor Group Holdings, Inc. | 400 | $24 | 0.00% | 00.0% | Unchanged |
| JPMorgan Chase & Co | 140 | $8 | 0.00% | +138+6,900.0% | Added |
| FNY Investment Advisers, LLC | 26,250 | – | – | 00.0% | Unchanged |
| Geode Capital Management, LLC | 0 | $0 | 0.00% | −157,445−100.0% | Sold out |
| HRT Financial LP | 0 | $0 | 0.00% | −79,562−100.0% | Sold out |
| Fifth Lane Capital, LP | 0 | $0 | 0.00% | −76,593−100.0% | Sold out |
| XTX Topco Ltd | 0 | $0 | 0.00% | −56,532−100.0% | Sold out |
| StoneX Group Inc. | 0 | $0 | 0.00% | −16,600−100.0% | Sold out |
| CI Private Wealth, LLC | 0 | $0 | 0.00% | −14,999−100.0% | Sold out |
| Jump Financial, LLC | 0 | $0 | 0.00% | −11,948−100.0% | Sold out |
| Pineridge Advisors LLC | 0 | $0 | 0.00% | −300−100.0% | Sold out |